🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Morgan Stanley maintains overweight on Salesforce stock

EditorAhmed Abdulazez Abdulkadir
Published 17/05/2024, 11:42
© Reuters
CRM
-

On Friday, Morgan Stanley (NYSE:MS) reaffirmed its Overweight rating on Salesforce (NYSE:CRM), with a consistent price target of $350.00. The firm's analysis suggests that while demand remains stable, investors should moderate their expectations due to typical first-quarter seasonality, underwhelming results from similar front-office companies, and foreign exchange headwinds.

The report indicated that these near-term concerns are balanced by a more optimistic medium-term perspective. Salesforce is seen as well-positioned to capitalize on the next generation of artificial intelligence, referred to as GenAI. Additionally, the valuation of Salesforce's stock was described as reasonable, which underpins the firm's decision to reiterate the Overweight rating.

Salesforce, a leader in customer relationship management software, has been under the watchful eye of analysts as it navigates the challenges and opportunities presented by the evolving technology landscape. The mention of GenAI highlights the potential for Salesforce to integrate cutting-edge AI technologies into its offerings, potentially enhancing its competitive edge in the market.

Morgan Stanley's analysis points to a careful balancing act for investors, weighing immediate market variables against the company's strategic positioning and financial attractiveness. The $350.00 price target suggests confidence in Salesforce's growth trajectory and its ability to adapt to industry changes.

As the market anticipates Salesforce's upcoming financial report, the insights from Morgan Stanley provide a snapshot of the company's current standing and future prospects. With its Overweight rating, the firm signals its belief that Salesforce's stock will outperform the average total return of stocks analyzed by Morgan Stanley over the next 12 to 18 months.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.